Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6698285

Nc1ccc(C2CCNCC2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.54
SIGMAR1 Q99720 4/20 0.49
SLC18A3 Q16572 1/20 0.49
P2RY14 Q15391 5/20 0.43
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
ITGA2 P17301 2/20 0.43
QDPR P09417 1/20 0.42
DRD5 P21918 4/20 0.42
TMEM97 Q5BJF2 4/20 0.42
ADRB3 P13945 3/20 0.42
ADRA2B P18089 3/20 0.42
DRD1 P21728 3/20 0.42
ADRA1B P35368 3/20 0.42
HTR1A P08908 2/20 0.42
SLC6A2 P23975 2/20 0.42
AGTR1 P30556 2/20 0.42
DRD3 P35462 2/20 0.42
SLC6A3 Q01959 2/20 0.42
PDE2A O00408 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL8528751 0.85 SLC18A3 (0.69) HTR2CSIGMAR1SLC18A3NAMPTJAK3
Trifluoroacetic Acid SCHEMBL6703422 0.85 HTR2C (0.51) HTR2CSIGMAR1SLC18A3P2RY14ITGB3
Trifluoroacetic Acid SCHEMBL2303613 0.84 HTR2C (0.78) HTR2CSIGMAR1SLC18A3P2RY14DRD5
SCHEMBL2266245 0.83 SLC18A3 (0.61) HTR2CSIGMAR1SLC18A3QDPRNAMPT
Trifluoroacetic Acid SCHEMBL3031403 0.81 PRKAB2 (0.44) SLC18A3ITGB3
Trifluoroacetic Acid SCHEMBL26600330 0.81 HTR2C (0.54) HTR2CSIGMAR1SLC18A3P2RY14ITGB3
Hydrochloric Acid SCHEMBL1203533 0.81 SLC18A3 (0.59) HTR2CSIGMAR1SLC18A3QDPRNAMPT
Trifluoroacetic Acid SCHEMBL942293 0.81 EPHX1 (0.52) HTR2CSIGMAR1SLC18A3P2RY14ITGB3
Trifluoroacetic Acid SCHEMBL381669 0.80 SLC18A3 (0.51) HTR2CSIGMAR1SLC18A3HTR1ASLC6A2
Trifluoroacetic Acid SCHEMBL31700691 0.79 HTR2C (0.48) HTR2CSIGMAR1SLC18A3P2RY14ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044008-A1 Use of therapeutic benzamide derivatives DAUGAN ALAIN CLAUDE-MARIE (FR) 2004-03-04 US disclosed
EP-1286670-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-03-05 EP disclosed
WO-2001097810-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044008-A1 Use of therapeutic benzamide derivatives MTTP, LIPC, CETP HTR2C 2767/4885SIGMAR1 1346/4885SLC18A3 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.